Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis.

Publication Year: 2023

DOI:
10.2147/TCRM.S361706

PMCID:
PMC10691373

PMID:
38047038

Journal Information

Full Title: Ther Clin Risk Manag

Abbreviation: Ther Clin Risk Manag

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Health Care Sciences & Services

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Dianna Quan reports grants, personal fees, non-financial support from Alnylam; grants from Ionis, Pfizer, Cytokinetics, Momenta, VielaBio, and Avidity Biosciences, outside the submitted work. Dr Stacy Dixon is a sub-investigator for APOLLO study and HELIOS-A study for Alnylam, outside the submitted work. The authors report no other conflicts of interest in this work."

Evidence found in paper:

"Disclosure: Dr Dianna Quan reports grants, personal fees, non-financial support from Alnylam; grants from Ionis, Pfizer, Cytokinetics, Momenta, VielaBio, and Avidity Biosciences, outside the submitted work. Dr Stacy Dixon is a sub-investigator for APOLLO study and HELIOS-A study for Alnylam, outside the submitted work. The authors report no other conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025